Tradestie Institutional Equity Comparison Engine
COCP vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Overall Edge
ANRO Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
COCP N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner
ANRO
Op Margin -3063.6% vs 0.0% ยท YoY +26.9% vs +0.0%
Momentum & Technical Winner
ANRO
1Y -3.0% vs +144.7% ยท 52W Pos 19% vs 64%
Options & Structure Winner
ANRO
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (8th %ile IV)
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap
$19.6M
1M Return
-2.01%
1Y Return
-2.96%
Forward P/E
N/M
Unified AI Score
47.1 / 100
HOLD
Tech 51.0
Fund 48.0
Flow 50.0
Mom 54.0
ANRO
NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.77
-5.99% 1D
Market Cap
$1.2B
1M Return
+26.57%
1Y Return
+144.67%
Forward P/E
N/M
Unified AI Score
29.3 / 100
SELL
Tech 50.0
Fund 34.0
Flow 65.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
COCP -2.96%
ANRO +144.67%
Spread: +147.63 pp (ANRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
COCP TTM Op. Margin: -3063.6%
ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on COCP vs ANRO. Trailing 12-month operating profitability (COCP -3063.6% vs ANRO 0.0%) and valuation multiples (COCP N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | COCP | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.6M | $1.2B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +26.9% | +0.0% | Higher Growth | COCP |
| Operating Margin (TTM) Profitability | -3063.6% | 0.0% | Higher Margin | ANRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -311.7% | -46.7% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 19% ($1โ$2) | 64% ($11โ$37) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 1.04ฮฒ ยท 54% Vol | 1.95ฮฒ ยท 89% Vol | Lower Realized Risk | COCP |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 29.3 / 100 (SELL) | Higher Composite | COCP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full COCP vs ANRO Buy Guide
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ANRO
CONSOLIDATION
57d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither COCP nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.